Growth Metrics

United Therapeutics (UTHR) Asset Writedowns and Impairment (2017 - 2022)

United Therapeutics' Asset Writedowns and Impairment history spans 5 years, with the latest figure at $4.2 million for Q4 2022.

  • On a quarterly basis, Asset Writedowns and Impairment rose 104.46% to $4.2 million in Q4 2022 year-over-year; TTM through Sep 2024 was $4.2 million, a 62.5% decrease, with the full-year FY2025 number at $21.7 million, changed N/A from a year prior.
  • Asset Writedowns and Impairment hit $4.2 million in Q4 2022 for United Therapeutics, down from $7.0 million in the prior quarter.
  • Over the last five years, Asset Writedowns and Impairment for UTHR hit a ceiling of $107.3 million in Q2 2021 and a floor of -$94.2 million in Q4 2021.
  • Historically, Asset Writedowns and Impairment has averaged $5.5 million across 4 years, with a median of $5.8 million in 2020.
  • Biggest five-year swings in Asset Writedowns and Impairment: surged 1450.0% in 2020 and later soared 104.46% in 2022.
  • Tracing UTHR's Asset Writedowns and Impairment over 4 years: stood at $8.8 million in 2019, then tumbled by 38.64% to $5.4 million in 2020, then plummeted by 1844.44% to -$94.2 million in 2021, then surged by 104.46% to $4.2 million in 2022.
  • Business Quant data shows Asset Writedowns and Impairment for UTHR at $4.2 million in Q4 2022, $7.0 million in Q3 2022, and -$94.2 million in Q4 2021.